Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Vivos Therapeutics ( (VVOS) ) is now available.
On January 15, 2026, Vivos Therapeutics entered into a warrant inducement agreement with an institutional holder under which the investor agreed to exercise in full previously issued warrants from January 2023, November 2023 and February 2024 at a reduced exercise price of $2.34 per share, generating approximately $4.6 million in gross proceeds for the company. In return, Vivos issued new Series A and Series B inducement warrants for a total of 3,964,712 shares at $2.09 per share in a private placement, with the inducement transaction closing on January 20, 2026, subject to resale registration obligations, restrictions on new equity issuance and variable-rate financings, and customary protections in the warrants, while H.C. Wainwright received cash fees, expense reimbursements and additional warrants as compensation. The company plans to use the net proceeds for working capital and general corporate purposes, a move that bolsters its near-term liquidity but also adds potential future equity dilution for existing shareholders.
The most recent analyst rating on (VVOS) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Vivos Therapeutics stock, see the VVOS Stock Forecast page.
Spark’s Take on VVOS Stock
According to Spark, TipRanks’ AI Analyst, VVOS is a Neutral.
The score is primarily held down by persistent losses, worsening cash burn, and a pressured balance sheet with higher leverage versus a thin equity base. Offsetting factors include strong recent revenue growth and a strategic pivot highlighted on the earnings call, but technicals remain weak and the recent financing underscores near-term funding and dilution risk.
To see Spark’s full report on VVOS stock, click here.
More about Vivos Therapeutics
Vivos Therapeutics, Inc. is a Delaware-based company whose common stock is listed on the Nasdaq Stock Market and which raises capital through private placements of equity-linked securities, including common stock purchase warrants issued to institutional investors and facilitated by investment bank H.C. Wainwright & Co.
Average Trading Volume: 139,212
Technical Sentiment Signal: Strong Sell
Current Market Cap: $19.54M
See more insights into VVOS stock on TipRanks’ Stock Analysis page.